Trial · NCT03628391
Haloperidol for Delirium in Adult Critically Ill Patients
NCT03628391, Phase 3, Terminated, Erasmus Medical Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Haloperidol for Delirium in Adult Critically Ill Patients. Trials, record NCT03628391. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03628391
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Haloperidol for Delirium in Adult Critically Ill Patients
- NCT number
- NCT03628391
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 142 participants, actual
- Lead sponsor
- Erasmus Medical Center
- Conditions
- Delirium, Critical Illness, Intensive Care Psychosis, Cognitive Impairment, Cognitive Decline
- Interventions
- Haloperidol, Placebo
- First posted
- 2018-08-14
- Last updated
- 2022-05-11
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | delirium- and coma-free days | within the first 14 days after randomisation | days without brain dysfunction (=delirium OR coma) while at the ICU |
| Secondary | Cognitive deterioration: Global cognitive functioning | 3 and 12 months | Global cognitive functioning as assessed with the Montreal Cognitive Assessment (MOCA). Total score will be reported, with a range of 0-30 (higher values representing better cognitive functioning). |
| Secondary | Cognitive deterioration: Verbal learning and memory | 3 and 12 months | Auditory-verbal learning and memory will be assessed with the Rey Auditory Verbal Learning Test. Three subscores will be reported: total correct words in 5 trials (range: 0 -75), total correct words after delay (range: 0-15) and total correct words at recognition (range: 0-30). |
| Secondary | Cognitive deterioration: Semantic fluency | 3 and 12 months | Semantic fluency will be tested with the Semantic Category Fluency Test. The amount of animals given within a time of 60 seconds will represent the score. |
| Secondary | Cognitive deterioration: Working memory | 3 and 12 months | Working memory will be assessed using the Wechsler Adult Intelligence Scale - Third Edition (WAIS-III). Subscales will be reported for both digit span under forward and backward recall conditions. In addition, a total score will be reported, which equals the sum of both separate digit spans. |
| Secondary | Cognitive deterioration: Cognitive flexibility | 3 and 12 months | Cognitive flexibility, one of the executive funcions, will be assessed with the Trialmaking tests A and B. The total amount of seconds needed to finish each test will be reported, with less seconds needed representing better cognitive flexibility. |
| Secondary | Cognitive deterioration: Word retrieval | 3 and 12 months | Word retrieval is tested with the Boston Naming Test (30-item version). The total score (range: 0-30) represents the amount of correct answered drawings. |
| Secondary | Anxiety and depression | 3 and 12 months | Anxiety and depression will be assessed with the Hospital Anxiety and Depression Scale (HADS). Two subscales will be reported, one for anxiety symptoms (range: 0-21) and one for depression symptoms (range: 0-21). Higher values represent a worse outcome. A subscore \>8 indicates anxiety or depression, respectively. |
| Secondary | Functional outcome | 3 and 12 months | Health-related quality of life will be assessed with the Short Form-35 (SF-36). Nine subscales will be reported on a 0 - 100 scale: physical functioning, role functioning - physical, bodily pain, general health, vitality, social functioning, role functioning - emotional, mental health and reported health transition. Higher values represent a better health-related quality of life. |
| Secondary | mortality | 28 days and 1 year | mortality |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03628391
GET https://conductscience.org/api/trials/v1/NCT03628391/registered